Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 6/20 | 0.57 |
| ▸ | ABL1 | P00519 | 6/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659798 | 0.84 | ABL1 (0.57) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL2739755 | 0.80 | ABL1 (0.48) | ABL1 | |
| SCHEMBL3659787 | 0.80 | WNT3A (0.51) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL4349216 | 0.74 | MAPK1 (0.74) | PIK3CA | |
| SCHEMBL3757870 | 0.74 | ABL1 (0.48) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL3661487 | 0.73 | ABL1 (0.57) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| Hydrochloric Acid SCHEMBL1843076 | 0.73 | FGFR1 (0.43) | ABL1FGFR1 | |
| SCHEMBL15464086 | 0.73 | LIPC (1.00) | LIPCLIPG | |
| SCHEMBL3662294 | 0.72 | ABL1 (0.59) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL3662159 | 0.72 | ABL1 (0.51) | ABL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231653-B1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2013-04-03 | — | — | EP | claimed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | claimed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-2231653-B1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2013-04-03 | — | — | EP | disclosed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2231653-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | Biota Europe Ltd (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074812-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | PROLYSIS LTD (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | LIPC 1715/4885ABL1 294/4885LIPG 1580/4885 |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | NEK6, NEK1, TXK | LIPC 4087/4885ABL1 89/4885LIPG 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.